Want to see LNSR full AI Analyst Report?
LENSAR (LNSR) AI Stock Analysis
Top Page
LENSAR
(NASDAQ:LNSR)
The score is primarily constrained by weak cash flow (negative operating and free cash flow) and questions around the durability/quality of recent reported profitability, despite low leverage. Offsetting this are constructive earnings-call fundamentals (recurring revenue strength, procedure and installed-base growth, improving profitability) and a low P/E that supports valuation. Technically, momentum is positive, but overbought readings increase near-term pullback risk.
LENSAR (LNSR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $71.75M
- Dividend Yield
- ―
- Average Volume (3M)
- 104.07K
- Price to Earnings (P/E)
- 4.6
- Beta (1Y)
- 0.97
- Revenue Growth
- 3.26%
- EPS Growth
- ―
- Country
- US
- Employees
- 150
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
LENSAR Business Overview & Revenue Model
Company Description
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, E...
LENSAR Earnings Call Summary
The call presented clear operational and financial improvements: double‑digit revenue growth (18% total, 20% recurring), strong procedure growth (23% procedure revenue, 13% volume), expanding installed base and the best adjusted EBITDA to date. These positives are tempered by a lower cash balance, reliance on a $1.1M tariff refund that boosted gross margin, near-term seasonality, expected normalization of operating expenses as commercial investments resume, and some timing/pricing uncertainty around backlog and distributor re-engagement. On balance, the fundamental business momentum (recurring revenue mix, procedures, ALLY adoption and profitability improvement) outweighs the short-term risks and one-time items.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management's forward guidance was that operating expenses will "gradually" increase as the company reinvests in commercial efforts—trending modestly higher toward historical levels—which will likely cause some variability in GAAP net income and adjusted EBITDA over the next several quarters; they also reminded investors of seasonal softness in Q3 (historically the lowest quarter) and that new ALLY installs typically take ~60–90 days to ramp. Near‑term visibility includes a backlog of 13 ALLY systems, 10 ALLY placements in Q2, an installed base of ~215 ALLY systems (445 total systems globally), and Q2 operating results of $16.5M revenue (+18% YoY), $13.7M recurring revenue (83% of total, +20% YoY), $10.2M procedure revenue (+23% YoY), 58,682 procedures (+13% YoY), cash of $13.6M, gross margin ~52% ex‑tariff refund, and Q2 adjusted EBITDA of $3.6M (strongest to date); they expect ALLY system pricing to remain relatively flat with modest ASP creep as U.S. mix grows.
LENSAR Financial Statement Overview
Summary
Reported profitability has improved sharply in the TTM (strong net margin and solid gross margin) and leverage is low, but earnings quality is a concern given the mismatch between negative EBIT and positive net income plus a history of operating losses. The biggest weakness is cash generation: TTM operating cash flow and free cash flow are negative with deteriorating FCF, increasing funding risk if burn persists.
Income Statement
62PositiveBalance Sheet
58NeutralCash Flow
28Negative| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 60.26M | 58.44M | 53.49M | 42.16M | 35.36M | 34.46M |
| Gross Profit | 28.90M | 27.12M | 25.85M | 21.11M | 19.95M | 17.83M |
| EBITDA | 36.46M | -29.78M | -3.00M | -10.87M | -16.51M | -16.84M |
| Net Income | 34.70M | -34.28M | -31.40M | -14.38M | -19.91M | -19.60M |
Balance Sheet | ||||||
| Total Assets | 69.56M | 71.43M | 66.30M | 69.58M | 55.84M | 66.47M |
| Cash, Cash Equivalents and Short-Term Investments | 13.56M | 17.98M | 22.45M | 24.06M | 14.67M | 31.64M |
| Total Debt | 2.38M | 2.73M | 2.61M | 2.31M | 2.80M | 3.31M |
| Total Liabilities | 54.65M | 97.45M | 47.65M | 22.41M | 13.86M | 11.59M |
| Stockholders Equity | 14.90M | -26.02M | 18.65M | 47.18M | 41.98M | 54.88M |
Cash Flow | ||||||
| Free Cash Flow | -7.33M | -14.91M | -2.43M | -9.89M | -14.97M | -9.32M |
| Operating Cash Flow | -7.29M | -14.83M | -2.27M | -9.66M | -14.86M | -8.97M |
| Investing Cash Flow | 13.21M | 1.28M | -2.16M | -4.16M | -115.00K | -354.00K |
| Financing Cash Flow | 498.00K | 10.26M | 78.00K | 19.76M | -1.99M | 361.00K |
LENSAR Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LNSR, the sentiment is Negative. The current price of 5.84 is below the 20-day moving average (MA) of 6.11, below the 50-day MA of 7.10, and below the 200-day MA of 7.45, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 34.57 is Neutral, neither overbought nor oversold. The STOCH value of 51.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LNSR.
LENSAR Risk Analysis
LENSAR disclosed 67 risk factors in its most recent earnings report. LENSAR reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskLENSAR Peers Comparison
Overall Rating
- LNSR62Neutral
SGHT57.9Neutral
HYPR57Neutral
RCEL54Neutral
RPID41Neutral
TELA34Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| LNSR | 62Neutral | $71.75M | 4.60 | 9999.00% | ― | 3.26% | ― |
| SGHT | 58Neutral | $513.42M | -16.69 | -50.64% | ― | 9.27% | 41.98% |
| HYPR | 57Neutral | $76.10M | -1.87 | -100.30% | ― | 53.16% | 27.17% |
| RCEL | 54Neutral | $484.01M | -10.79 | 231.87% | ― | 1.00% | 26.76% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| RPID | 41Neutral | $36.91M | -0.66 | -177.04% | ― | 16.13% | -11.56% |
| TELA | 34Underperform | $36.57M | -1.05 | 1248.13% | ― | 6.09% | 30.65% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| LNSR | Lensar Inc | 5.84 | -6.66 | -53.28% | |
| RCEL | Avita Medical Ltd | 15.65 | 11.87 | 314.02% | |
| TELA | Tela Bio, Inc. | 0.81 | -0.56 | -40.88% | |
| HYPR | Hyperfine Inc. | 0.72 | -0.41 | -36.55% | |
| SGHT | Sight Sciences, Inc. | 9.32 | 4.22 | 82.75% | |
| RPID | Rapid Micro Biosystems, Inc. Class A | 0.73 | -2.02 | -73.27% |
LENSAR Corporate Events
LENSAR Shareholders Approve Directors and Executive Pay
PositiveOn August 4, 2026, LENSAR held its annual meeting of stockholders, with approximately 90.53% of the company’s total voting power represented in person or by proxy. Stockholders considered four proposals relating to board composition, auditor ra...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026